التفاصيل البيبلوغرافية
| العنوان: |
Paclitaxel-Ifosfamide-based Therapy as Salvage Treatment in Platinum-resistant Recurrent/Metastatic Head and Neck Cancer. |
| المؤلفون: |
MING-YU CHOU, WEN-CHI WU, PEN-YUAN CHU, SHYH-KUAN TAI, MU-HSIN CHANG, PETER, TSUNG-LUN LEE, TIEN-HUA CHEN, MUH-HWA YANG |
| المصدر: |
In Vivo; Jul/Aug2024, Vol. 38 Issue 4, p1891-1899, 9p |
| مصطلحات موضوعية: |
PACLITAXEL, IFOSFAMIDE, HEAD & neck cancer treatment, MEDICATION safety, DRUG efficacy |
| مستخلص: |
Background: Treatment options are limited, and the prognosis is poor for patients with platinum-resistant recurrent metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). This study evaluated the efficacy and safety of a paclitaxel and ifosfamide (TI) regimen in patients with R/M HNSCC whose disease had progressed following platinum-based therapy. Patients and Methods: In this retrospective study, we included 53 patients with R/M HNSCC who underwent at least one cycle of TI-based therapy, post platinum failure, between February 2020 and August 2023. Some patients received the TI regimen in combination with immunotherapy and/or cetuximab. Key metrics assessed included the objective response rate (ORR), disease control rate, and progression-free as well as overall survival. Results: The study observed an ORR of 15.8% and a disease control rate of 36.8%. The median progression-free survival for the entire cohort was 3.3 months, and the median overall survival was 9.6 months. Notably, the combination of TI with immunotherapy yielded a higher ORR of 30.8%, compared to 14.3% with TI alone. The most prevalent grade 1-2 adverse events were anemia (81%), weight loss (68%) and hypernatremia (55%). Conclusion: The TI-based regimen demonstrated favorable efficacy and safety profile in treating R/M HNSCC. Enhanced outcomes may be attainable when combining it with immunotherapy. This study suggests that TI-based therapy could serve as a potential salvage option for this specific patient group. [ABSTRACT FROM AUTHOR] |
|
Copyright of In Vivo is the property of International Institute of Anticancer Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
